Mylan beats Sanofi appeal in insulin-pen patent fight | Reuters
Mylan Pharmaceuticals Inc., a Viatris Company, Issues Voluntary Nationwide Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection Pens, 100 units/mL (U-100), Due to the Potential of Missing Labels on Some
Dose Disparity: The Improper Use of an Insulin Glargine Pen: A Case Report - Natalie Nienhaus, Jennifer Alisha Rivas, Kimberly A. B. Cauthon, 2021
How to use SoloStar Pen for Injecting Lantus (Glargine) and Apidra (Glulisine) Insulin - YouTube